Aardvark Therapeutics, Inc.
AARD
$11.81
-$0.14-1.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | -- | -- | -- | 3.16M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -- | -- | 7.85M | |
| Operating Income | -- | -- | -- | -7.85M | |
| Income Before Tax | -- | -- | -- | -7.86M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -- | -- | -- | -7.86 | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -- | -- | -7.86M | |
| EBIT | -- | -- | -- | -7.85M | |
| EBITDA | -- | -- | -- | -2.17M | |
| EPS Basic | -- | -- | -- | -1.98 | |
| Normalized Basic EPS | -- | -- | -- | -1.09 | |
| EPS Diluted | -- | -- | -- | -1.98 | |
| Normalized Diluted EPS | -- | -- | -- | -1.09 | |
| Average Basic Shares Outstanding | -- | -- | -- | 15.85M | |
| Average Diluted Shares Outstanding | -- | -- | -- | 15.85M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |